Debio 1347

Solid tumors

Debio 1347 is an orally available small molecule targeting FGFR 1, 2, 3 signaling pathways . Debio 1347 is currently in phase I for the treatment of advanced solid tumors. It already showed anti-cancer efficacy in several in vivo preclinical animal models. Debio 1347 is expected to become a tailored treatment which will be developed with a companion diagnostic.



Press Releases

All Press Releases


All Publications